Gt Biopharma, Inc. · NASDAQ:GTBP
Gt Biopharma — Investor Presentation (September 2026)
21 slides from Gt Biopharma's investor presentation, September 2026
Slide 1: Tri-Specific NK Cell ENGAGERS (TriKE®)
Tri-Specific NK Cell ENGAGERS (TriKE®) Targeted NK Cell Therapies to Treat Cancer and Autoimmune Disease GT Biopharma (Nasdaq: GTBP) Corporate Presentation – September 2026
Slide 2: Disclaimer
Disclaimer This presentation includes statements that are, or may be deemed, “forward-looking statements.” In some cases, you can identify forward-looking statements by terminology including “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “po
Slide 3: Investment Opportunity – Next Generation of NK Cell ENGAGERS
Investment Opportunity – Next Generation of NK Cell ENGAGERS Proprietary TriKE® • TriKE® are tri-specific NK cell ENGAGERS Platform – Camelid • Incorporate Camelid “nanobodies” Nanobodies • Protein therapeutics to harness the natural killing power of NK cells with – NOT NK cell therapy NK Cell ENGAG
Slide 4: GTB-3550 AML/MDS Phase 1 Study Design
GTB-3550 AML/MDS Phase 1 Study Design Dose Level 1 5 µg/kg/day (n=2) Dose Level 2: 10 µg/kg/day (n=2) Screening / Dose Level 3: enrollment: 25 µg/kg/day (n=2) - R/R AML ≥ 50% CD33+ - HR MDS Dose Level 4: Disease target cells 50 µg/kg/day (n=2) Re-assessment with no SOC (> 2 prior lines) Day 28 – 42
Slide 5: GTB-3550 Activation of Endogenous NK Cells
GTB-3550 Activation of Endogenous NK Cells Panel A: Increase in NK cell activation upon administration of GTB-3550 Panel B: Increase in absolute number of NK cells during treatment (n= 2 patients per dose) (n= 2 patients per dose) 100 12000 5 ug/kg 5 ug/kg 10000 10 ug/kg 10 ug/kg 8000 25 ug/kg 25 ug
Slide 6: GTB-3550 First in Human Phase 1 Clinical Trial – Individual Results
GTB-3550 First in Human Phase 1 Clinical Trial – Individual Results Disease Disease Dose level Response Subject Disease and Prior Treatment History Characteristics Before Characteristics After (µg/kg/d) Post Cycle 1 GTB-3550 Therapy GTB-3550 Therapy r/r AML. Triple Hit Lymphoma - 6 therapies: 1. R-E
Slide 7: TriKE® Nanobody Pipeline
TriKE® Nanobody Pipeline TriKE® Product IND-Enabling/ Candidates Approach Target Indication Pre-Clinical GMP Manufacturing Phase 1 Phase 2 Leukemia – AML, GTB-3650 Monotherapy CD33 GTB-3650 MDS 2nd Generation Phase 1 trial, Combination first 4 cohorts Camelid Leukemia – AML, with CD33 Chemotherapy M
Slide 8: Natural Killer Cell ENGAGERS to Fight Cancer
Natural Killer Cell ENGAGERS to Fight Cancer Natural Killer Cells • Cytotoxic lymphocytes in the innate immune system • Recognize and kill cancer cells • Mediate antibody-dependent cellular cytotoxicity (ADCC) via the highly potent CD16 activating receptor NK Cell ENGAGERS • TriKE® nanobody platform
Slide 9: TriKE®: Tri-Specific Natural Killer (NK) Cell ENGAGERS - A Modular Platform
TriKE®: Tri-Specific Natural Killer (NK) Cell ENGAGERS - A Modular Platform Proprietary platform utilizing camelid nanobody technology designed to bridge NK cells to tumor cells while inducing NK cell activation and expansion at the site of the tumor to enhance killing Tri-specific Modular Platform
Slide 10: TriKE® Modular Platform Allows for Multiple Tumor-Associated Antigen
TriKE® Modular Platform Allows for Multiple Tumor-Associated Antigen CD33 Myeloid Cell CD19 B cell Hematological CD22 or BCMA B cell Malignancies scFv Nanobody CLEC12A Myeloid Cell Anti-Tumor Associated Antigen CD133 Cancer Stem Cell • Binds to well-known tumor-specific antigens Pan Tumor & MM B7H3
Slide 11: TriKE® – NK Cell-Driven Serial Killing of AML Tumor Cells
TriKE® – NK Cell-Driven Serial Killing of AML Tumor Cells • First-in-class modular immune oncology protein therapeutic platform technology – not a cell therapy • Target-directed antibody-dependent cellular cytotoxicity (ADCC) killing • Integrated CD16 and IL-15 driven activation of NK cells: • ADCC
Slide 12: GTB-3550 Phase 1 Demonstrates Proof of Concept for CD33 TriKE® in AML/MDS
GTB-3550 Phase 1 Demonstrates Proof of Concept for CD33 TriKE® in AML/MDS • GTB-3550 induces reproducible NK cell proliferation, activation and persistence in all patients at all dose levels with minimal clinically significant toxicity • Minimal CRS resulting from hyperactivation of patient’s T-cell
Slide 13: GTB 3650 for AML and MDS
GTB 3650 for AML and MDS GTB 5550 for Solid Tumors Second generation TriKEs® utilize camelid nanobody technology 13
Slide 14: Advantages of Camelid Antibodies – Nanobodies in 2nd Generation TriKEs®
Advantages of Camelid Antibodies – Nanobodies in 2nd Generation TriKEs® • Camelidae family of mammals include llamas, camels, and alpacas • Camelid antibody is made up of only 2 heavy chains VH CH1 • Heavy chain IgG (hcIgG) V HH VL • Do not contain the CH1 region CL • Retain an antigen binding domai
Slide 15: Our Approach – Co-Stimulation of CD16 and IL-15
Our Approach – Co-Stimulation of CD16 and IL-15 TriKE® Competitive Differentiation NKp46/CD16 CD16A NKG2D/CD16 • The anti-CD16 component of the TriKE® binds FcRIII with high affinity • TriKE® does not result in proliferation of T-cells • NK cell ENGAGER/antibody therapeutic strategies designed to e
Slide 16: GTB 5550 - B7H3 TriKE Killing of Prostate Cancer
GTB 5550 - B7H3 TriKE Killing of Prostate Cancer GTB 5550 NK Cells Alone NK Cells+IL-15 NK Cells+B7H3 TriKE ® 16
Slide 17: GTB 7550 for Autoimmune Disease
GTB 7550 for Autoimmune Disease Targeting CD19 for B-Cell Depletion In Vivo 17
Slide 18: GTB 7550 for Autoimmune Disease
GTB 7550 for Autoimmune Disease • GTB-7550 TriKE® product candidate is in development for the treatment of lupus and other autoimmune disorders • GTB-7550 TriKE® is a tri-specific molecule composed of a camelid nanobody that binds the CD16 receptor on NK cells, a scFv ENGAGER against CD19 on maligna
Slide 19: Experienced Team With Deep Immuno-Oncology Experience
Experienced Team With Deep Immuno-Oncology Experience Proven Record in Biotech, Pharma, Product Development, Financing Michael Breen, LL.B Alan Urban Jeffrey Miller, MD Martin Felices, PhD Chris Hendry Hilary Kramer David C. Mun-Gavin Charles J Casamento Executive Chairman and Chief Financial Office
Slide 20: Recent M&A and BD Deals Highlight Value of NK Cell ENGAGERS and Immuno-Oncology
Recent M&A and BD Deals Highlight Value of NK Cell ENGARERS and Immuno-Oncology Innovator Acquirer Date 8/27/2018 11/9/2020 12/21/2021 5/2/2022 12/19/22 Collaboration Single Molecule Single Molecule Deal Type License Deal Preclinical License Deal Company Acquisition Preclinical License Deal Expansio
Slide 21: Contact Us
Contact Us Michael Breen, Exec. Chairman & CEO Investor Relations Contact: Alan Urban, CFO Corey Davis, Ph.D. GT Biopharma, Inc. LifeSci Advisors 505 Montgomery Street, 10th Floor cdavis@lifesciadvisors.com San Francisco, CA 94111 212-915-2577 ir@gtbiopharma.com 415-919-4040 For more information, pl
GT Biopharma — Investor Presentation (September 2026) on 6ix